Edition:
United States

vTv Therapeutics Inc (VTVT.OQ)

VTVT.OQ on NASDAQ Stock Exchange Global Market

1.64USD
23 May 2018
Change (% chg)

-- (--)
Prev Close
$1.64
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
223,703
52-wk High
$8.37
52-wk Low
$0.65

Chart for

About

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting... (more)

Overall

Beta: --
Market Cap(Mil.): $53.81
Shares Outstanding(Mil.): 32.81
Dividend: --
Yield (%): --

Financials

  VTVT.OQ Industry Sector
P/E (TTM): -- 237.88 32.90
EPS (TTM): -0.93 -- --
ROI: -353.98 -7.38 12.74
ROE: -- -10.11 14.64

BRIEF-vTv Therapeutics Q1 GAAP Loss Per Share $0.30

* VTV THERAPEUTICS REPORTS 2018 FIRST QUARTER FINANCIAL AND OPERATIONAL RESULTS AND RECENT HIGHLIGHTS

May 15 2018

BRIEF-VTV Therapeutics Announces Company Will Pre-Specify New Subgroup With The FDA

* VTV THERAPEUTICS ANNOUNCES COMPANY WILL PRE-SPECIFY NEW SUBGROUP WITH THE FDA AND REPORT PHASE 3 PART B RESULTS IN JUNE

May 09 2018

BRIEF-Vtv Therapeutics Announces Topline Results From The First Steadfast Phase 3 Study Evaluating Azeliragon In People With Mild Alzheimer's Disease

* VTV THERAPEUTICS ANNOUNCES TOPLINE RESULTS FROM THE FIRST STEADFAST PHASE 3 STUDY EVALUATING AZELIRAGON IN PEOPLE WITH MILD ALZHEIMER’S DISEASE

Apr 09 2018

BRIEF-vTv Therapeutics Says Phase 1B Study Of TTP399 For The Treatment Of Type 1 Diabetes Completed

* VTV THERAPEUTICS ANNOUNCES COMPLETION OF PHASE 1B STUDY EVALUATING TTP399 FOR THE TREATMENT OF TYPE 1 DIABETES Source text for Eikon: Further company coverage:

Mar 22 2018

BRIEF-VTV Therapeutics Reports Q4 Loss Per Share $0.44

* VTV THERAPEUTICS REPORTS 2017 FOURTH QUARTER AND FULL YEAR FINANCIAL AND OPERATIONAL RESULTS AND RECENT HIGHLIGHTS

Feb 27 2018

BRIEF-vTv Therapeutics Files For Stock Shelf Of Up To $250 Million

* VTV THERAPEUTICS INC FILES FOR STOCK SHELF OF UP TO $250 MILLION – SEC FILING‍​ Source text for Eikon: (http://bit.ly/2EUHrux) Further company coverage:

Feb 27 2018

BRIEF-Vtv Therapeutics, Reneo Pharmaceuticals Enter Licensing Agreement

* VTV THERAPEUTICS AND RENEO PHARMACEUTICALS ENTER LICENSING AGREEMENT FOR PPAR-DELTA PROGRAM

Dec 21 2017

BRIEF-vTv Therapeutics Signs Agreement With Hangzhou Zhongmei For Rights of Glp-1R Agonist Diabetes Program

* VTV THERAPEUTICS INC SAYS LICENSING AGREEMENT WITH HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO. TO RIGHTS FOR VTV'S GLP-1R AGONIST DIABETES PROGRAM

Dec 21 2017

BRIEF-VTv Therapeutics Entered Into Agreement With MacAndrews & Forbes

* VTV THERAPEUTICS SAYS ON DEC 5, CO ENTERED INTO A LETTER AGREEMENT WITH MACANDREWS & FORBES GROUP LLC - SEC FILING

Dec 06 2017

Earnings vs. Estimates